Slingshot Insights

Catalyst

Slingshot members are tracking this event:

Results of Phase 3 VITALITY-ALS Trial of Lead Drug Candidate Tirasemptiv Projected Q3 of 2017

Source Link:: http://services.corporate-ir.net/SEC/Document.Service?id=P3VybD1hSFIwY0RvdkwyRndhUzUwWlc1cmQybDZZWEprTG1OdmJTOWtiM2R1Ykc5aFpDNXdhSEEvWVdOMGFXOXVQVkJFUmlacGNHRm5aVDB4TURjNU5EQTBNaVp6ZFdKemFXUTlOVGM9JnR5cGU9MiZmbj1DeXRva2luZXRpY3NJbmMucGRm

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies

Importance

High

Medium

Low

Impact on Stocks

CYTK

100%

SIGN ME UP
I want to vote! LOG ME IN
Now!

Additional Information

Additional Relevant Details VITALITY-ALS, a Phase 3 clinical trial designed to assess the effects of tirasemtiv versus placebo on slow vital capacity and other measures of respiratory function in patients with ALS, began in July 2015 and results are expected in the third quarter of 2017. Tirasemptiv is Cytokinetic's lead drug candidate in development

http://services.corp...

Additional Relevant Details "We look forward to reporting results in the second half of 2017."

http://phx.corporate...

Slingshot Insights Explained

JOIN FOR FREE TODAY

Catalyst Date

Occurred on:

Nov 21, 2017

Occurred Source:

http://ir.cytokinetics.com/news-releases/news-release-details/cytokinetics-announces-negative-results-vitality-als

Related Projects

Don’t see a project related to the catalyst you care about?

Related Keywords Vitality-als, Phase 3 Study, Tirasemptiv, Als